Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 248

Similar articles for PubMed (Select 22822075)

1.

Effects of phosphate binders in moderate CKD.

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM.

J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.

2.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
3.

Effectiveness and cost-efficacy of phosphate binders in hemodialysis.

Brunner-Ziegler S, Fröschl B, Hiebinger C, Zsifkovits J.

Ann Nutr Metab. 2011 Oct;58(4):315-9. doi: 10.1159/000331988. Epub 2011 Oct 7.

PMID:
21986491
4.

Phosphate binders in CKD: bad news or good news?

Drüeke TB, Massy ZA.

J Am Soc Nephrol. 2012 Aug;23(8):1277-80. doi: 10.1681/ASN.2012060569. Epub 2012 Jul 12. No abstract available.

5.

Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?

Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM.

Clin J Am Soc Nephrol. 2010 Feb;5(2):286-91. doi: 10.2215/CJN.05420709. Epub 2009 Nov 12.

6.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488. Epub 2008 Sep 27.

7.

Hyperphosphatemia and phosphate binders: effectiveness and safety.

Kalaitzidis RG, Elisaf MS.

Curr Med Res Opin. 2014 Jan;30(1):109-12. doi: 10.1185/03007995.2013.841667. Epub 2013 Oct 9.

PMID:
24007207
8.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

9.

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.

Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006023. doi: 10.1002/14651858.CD006023.pub2. Review.

PMID:
21328279
10.

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C.

Am J Kidney Dis. 2012 Feb;59(2):177-85. doi: 10.1053/j.ajkd.2011.11.007. Epub 2011 Dec 2.

PMID:
22137672
11.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Chen N, Wu X, Ding X, Mei C, Fu P, Jiang G, Li X, Chen J, Liu B, La Y, Hou F, Ni Z, Fu J, Xing C, Yu X, Huang C, Zuo L, Wang L, Hunter J, Dillon M, Plone M, Neylan J.

Nephrol Dial Transplant. 2014 Jan;29(1):152-60. doi: 10.1093/ndt/gft232. Epub 2013 Oct 22.

PMID:
24151017
12.

A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease.

Qunibi W, Winkelmayer WC, Solomon R, Moustafa M, Kessler P, Ho CH, Greenberg J, Diaz-Buxo JA.

BMC Nephrol. 2011 Feb 16;12:9. doi: 10.1186/1471-2369-12-9.

13.

Pharmacology, efficacy and safety of oral phosphate binders.

Hutchison AJ, Smith CP, Brenchley PE.

Nat Rev Nephrol. 2011 Sep 6;7(10):578-89. doi: 10.1038/nrneph.2011.112. Review.

PMID:
21894188
14.

The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.

Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M, Martín-Malo A, Aljama P.

Clin Nephrol. 2013 Jul;80(1):17-22. doi: 10.5414/CN107764.

PMID:
23391319
15.

Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.

Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K.

Clin Nephrol. 2012 Sep;78(3):216-23.

PMID:
22874110
16.

Optimal use of phosphate binders in chronic kidney disease.

Sonikian M, Papachristou E, Goumenos DS.

Expert Opin Pharmacother. 2013 Dec;14(18):2521-32. doi: 10.1517/14656566.2013.852183. Epub 2013 Nov 12. Review.

PMID:
24215605
17.

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W.

Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85. doi: 10.2215/CJN.02830608. Epub 2008 Dec 3.

18.

Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?

Evenepoel P, Meijers B.

Nat Rev Nephrol. 2012 Nov;8(11):615-6. doi: 10.1038/nrneph.2012.219. Epub 2012 Oct 9. No abstract available.

PMID:
23045230
19.
20.

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

Sprague SM.

Curr Med Res Opin. 2007 Dec;23(12):3167-75. Review. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):708.

PMID:
17991307
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk